北京：以创新之力守护民生健康

Group 1 - The "Beijing Brain No. 1" brain-computer interface system has enabled high-level paraplegic patients to perform actions like grasping a cup using only their thoughts, showcasing innovation in the medical field [1] - The Beijing medical and health industry is projected to reach a total scale of 1.06 trillion yuan by 2024, driven by innovation in medical devices and AI, with the highest number of approved innovative medical devices in the country [1] - The Beijing Economic and Technological Development Zone hosts over 5,000 biopharmaceutical companies, covering all areas of the medical and health industry, including biopharmaceuticals, modern traditional Chinese medicine, new vaccines, and high-end medical equipment [1] Group 2 - AstraZeneca has officially launched its global R&D strategic center in Beijing, which will leverage the local scientific ecosystem and AI advantages to accelerate the development of next-generation innovative drugs [2] - The Beijing government has implemented a series of "32 measures" to address industry development bottlenecks, significantly reducing the median time for clinical trial initiation to 21.4 weeks and expediting the approval process for innovative drug projects [2] - Beijing is promoting dual-directional efforts in basic research and results transformation through targeted policies in synthetic biology, cell, and gene therapy, with a new gene drug for treating blindness set to begin trials in January 2024 [3] Group 3 - A new 20 billion yuan special industrial fund has been established to support the pharmaceutical and health sector, with 77 projects already approved for funding [3] - The "South-North linkage" strategy in Beijing aims to create a synergistic spatial layout, with the southern economic development zone focusing on global pharmaceutical talent and the northern area concentrating on original innovation and future industries [3] - The Beijing government plans to accelerate the integration of technological innovation and industrial innovation in the pharmaceutical industry, enhancing the smart and green levels of the entire pharmaceutical industrial chain [4]